3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
16
Phase 1/2
13
Phase 1
13
Phase 3
6
Phase NA
2
Phase 4
2
Phase 2/3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
44
Lymphoma
25
Leukemia
20
Lymphoma, Large B-Cell, Diffuse
19
Lymphoma, Non-Hodgkin
15
Neoplasms
14
Lymphoma, Follicular
14
Recurrence
10
Myelodysplastic Syndromes
10
Leukemia, Myeloid, Acute
10
Hematologic Neoplasms
8
Burkitt Lymphoma
8
Leukemia, Lymphocytic, Chronic, B-Cell
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Hodgkin Disease
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Neoplasms, Plasma Cell
5
Neoplasms by Site
5
Neoplasms by Histologic Type
5
Multiple Myeloma
5
Lymphoproliferative Disorders
5
Lymphoma, Mantle-Cell
5
Infections
5
Graft vs Host Disease
5
Lymphoma, B-Cell, Marginal Zone
4
Lymphoma, B-Cell
4
Leukemia, Biphenotypic, Acute
4
Anemia, Refractory, with Excess of Blasts
4
Lymphoma, T-Cell, Peripheral
3
Leukemia, T-Cell
3
Interventions
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Immunoproliferative Disorders
×
Lymphoid
×
Clear all
NCT01277172
2011-01-14
TREND
Probiomed S.A. de C.V.
Phase 2/3
Unknown
54 enrolled